ClinicalTrials.gg
Enrolling by invitationNCT07155967Updated Sep 16, 2026

Effect of Cross-Education in Blood Flow Restriction Resistance Training on Lower Limbs in Older Women

An interventional study of Blood Flow Restriction Cuff in Muscle Strength and Hypertrophy, sponsored by Paulista University. Enrolling by invitation at 1 site in Brazil. Open to female participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Paulista University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
60 Years and older
Sex
Female
01

Study summary

Unilateral resistance training has been shown to promote strength adaptations in the directly trained limb and also improve strength in the contralateral limb, a phenomenon known as cross-education (CE), with more pronounced effects observed in high-load training. However, high-load resistance training may be unfeasible for older adults. Blood flow restriction (BFR) training emerges as a low-load alternative that reduces joint stress, is easy to apply, and has low cost. Although there is already evidence showing significant effects of CE during resistance training with BFR, gaps remain regarding its applicability in older adults. This study aims to evaluate the effects of CE in resistance training with BFR on the lower limbs of older women.

Read the detailed description

A randomized controlled clinical trial will be conducted with 32 older women aged 60 years or older. Participants will be randomly assigned to one of two groups: a low-intensity unilateral resistance training group with blood flow restriction (BFR) (experimental group) and a low-intensity unilateral resistance training group without BFR (control group). Baseline assessments will include the following: pain using the Visual Analog Scale (VAS); perception of recovery and discomfort using the Likert scale; perceived exertion using the Borg CR-10 scale; systolic and diastolic blood pressure measured via the auscultatory method; heart rate using a Polar portable heart rate monitor; oxygen saturation via pulse oximetry; quadriceps circumference using a measuring tape; muscle mass assessed by ultrasound; muscle tone, stiffness, and elasticity evaluated by myotonometry; cellular health and integrity using bioelectrical impedance analysis (BIA); functional performance through the Timed Up and Go test (TUG), the Short Physical Performance Battery (SPPB), and a test of agility and dynamic balance (AGIL); and muscle strength measured by the one-repetition maximum test (1RM). Following the baseline assessment, participants will undergo the training protocol according to their group assignment. Hemodynamic parameters-heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and oxygen saturation (SpO₂)-as well as perceptual measures (VAS, Likert scale, and CR-10) will be collected before and immediately after each training session. After three weeks of training, an intermediate evaluation of all outcomes will be performed, along with load adjustment. Following this, participants will complete an additional three weeks of training. One week after the conclusion of the intervention, a final evaluation of all outcomes will be conducted. Descriptive statistics and repeated-measures ANOVA will be used for data analysis, with a significance level set at p \< 0.05.

Participants will be duly informed about the procedures and objectives of this study, and after agreeing, they will sign an informed consent form, effectively becoming part of it. In the consent form, participants will be asked if they agree to the use of their data if they choose to withdraw from the study. Participants will also be asked for permission for the research team to share relevant data with people at universities participating in the research or regulatory authorities, where relevant. The study were approved to the Research Ethics Committee of FCT/UNESP, Presidente Prudente, SP, Brazil.

02

Conditions studied

  • Muscle Strength
  • Hypertrophy

Keywords

  • Elderly population
  • Strength training
  • Physical exercise
  • Lower limb
  • Blood flow restriction therapy
03

In context

Hypertrophy

139 studies on the registry are indexed under Hypertrophy; 22 are open to participants now.

This study's planned enrollment of 32 is close to the median of 34 across 112 interventional studies indexed under Hypertrophy.

Browse Hypertrophy studies →

Lead sponsor

Paulista University is the lead sponsor of 23 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Elderly women who present one or more of the following characteristics will not be included:

    1. a history of stroke, progressive neurological disease, or dementia;
    2. communication difficulties due to aphasia or hearing loss;
    3. any health condition that contraindicates or prevents physical exercise;
    4. a history of hip or knee surgery (e.g., arthroscopy or arthroplasty) or recent lower limb musculoskeletal injury that could impair performance during tests or training (e.g., osteoarthritis, osteoporotic fracture, muscle injury, and/or back pain in the past six months);
    5. use of supplements aimed at improving physical performance and/or muscle mass; or
    6. one or more predisposing risk factors for thromboembolism.

Exclusion criteria

Exclusion Criteria:

Participants will be excluded from the study if they use medications (analgesics or anti-inflammatory drugs) or other therapeutic interventions that could interfere with any outcomes, or if they sustain an injury resulting from the training and choose to withdraw from the study.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Low-intensity unilateral resistance training group with blood flow restriction

    This group will perform the training protocol, with the dominant lower limb (LL) executing the exercises using an occlusion cuff set at 40% of total occlusion pressure (TOP), applied continuously throughout the session, while the other limb will perform the exercises without BFR.

    Device: Blood Flow Restriction Cuff

  • No intervention
    Low-intensity bilateral resistance training group without blood flow restriction

    This group will perform the training protocol on both limbs (bilaterally) without the use of blood flow restriction (BFR).

Interventions

  • DeviceBlood Flow Restriction Cuff

    Inflatable device that exerts an external pressure above a muscle or joint of the extremities.

06

What researchers measure

Primary outcomes

  1. Muscle strength assessment

    The one-repetition maximum (1RM) test will be used to assess muscle strength, as well as to prescribe the training protocol. It will be performed bilaterally during the initial, intermediate, and final assessments. Initially, participants will perform one repetition to familiarize themselves with the knee extension movement, followed by 10 warm-up repetitions using a load of 30-40% of the estimated 1RM. After the warm-up, the test will begin with a load equivalent to 20% of the participant's body mass, considering the target muscle group (quadriceps muscle). Load will then be progressively increased by 5-10% with each attempt. The participant must perform only one repetition per attempt. If successful, a rest interval of 3 to 5 minutes will be given before the next load increment and attempt. The 1RM is defined as the highest load the participant can lift once with proper form, without any compensatory movements. The test is considered valid if the participant reaches their maximum.

    Time frame: 3 days (baseline, mid-intervention, and final assessment)

  2. Ultrasound

    The assessment of the muscular structure will be carried out using ultrasound images of the participant's lower limbs, which will be captured using BodyMetrix BX-2000. Participants will be assessed in the supine position with legs fully extended and muscles relaxed. The ultrasound transducer will be covered with water-soluble transmission gel and positioned perpendicular to the skin over the muscle.

    Time frame: 3 days (baseline, mid-intervention, and final assessment)

  3. Quadriceps circumference

    Thigh circumference measurements will be taken at the proximal, medial, and distal positions, with the participant standing upright, heels approximately 10 cm apart, and body weight evenly distributed between both feet. For all measurements, the evaluator should position themselves so that their line of sight is level with the measurement site. Three non-consecutive measurements will be performed at each site, and the highest value will be recorded. A marker pen will be used to identify the exact anatomical locations for measurement.

    Time frame: 3 days (baseline, mid-intervention, and final assessment)

  4. Arterial pressure

    It will be collected with a sphygmomanometer

    Time frame: 9 weeks (at baseline, mid-intervention, and post-intervention, as well as before and immediately after training sessions)

  5. Heart rate

    Heart rate will be continuously monitored using a portable heart rate monitor, Polar® RS800cx model (Polar Electro OY, Finland).

    Time frame: 9 weeks (at baseline, mid-intervention, and post-intervention, as well as before and immediately after training sessions)

  6. Oxygen saturation

    Oxygen saturation will be measured using a fingertip pulse oximeter (ChoiceMMED - MD300C1 Fingertip, China), attached to the right index finger of each participant.

    Time frame: 9 weeks (at baseline, mid-intervention, and post-intervention, as well as before and immediately after training sessions)

  7. Subjective Pain Assessment

    Subjective pain assessment will be obtained using the Visual Analog Scale (VAS), graded from 0 to 10, with zero indicating no pain and 10 representing the maximum level of pain tolerated by the participant, as described by Ferreira et al. Participants will be asked about the presence of pain in the dominant and non-dominant lower limbs, identifying on the scale the number corresponding to their current pain intensity.

    Time frame: 9 weeks (at baseline, mid-intervention, and post-intervention, as well as before and immediately after training sessions)

  8. Subjective Perception of Discomfort

    Subjective perception of discomfort will be assessed using the Borg CR-10 scale, representing the perception of discomfort, with 0 corresponding to "no discomfort" and 10 to "maximum discomfort." Participants will be asked to report the discomfort perceived immediately after unilateral training with blood flow restriction (BFR). It should be noted that although the Borg CR-10 scale is not specifically designed for this purpose, it is commonly used in the BFR literature. The scale will be presented to participants in a way that prevents influence from the researcher.

    Time frame: 6 weeks (immediately after the training sessions)

  9. Subjective Perception of Recovery

    Subjective perception of recovery of the lower limb subjected to the exercise protocol will be assessed using a 10-point Likert scale, where 1 indicates "not recovered" and 10 "fully recovered." The scale will be presented to participants in a way that prevents influence from the researcher. The question will first be asked for the dominant lower limb and subsequently for the non-dominant lower limb.

    Time frame: 9 weeks (at baseline, mid-intervention, and post-intervention, as well as before and immediately after training sessions)

  10. Subjective Perception of Effort

    The Borg Rating of Perceived Exertion (RPE) scale (45) is an instrument used to assess the subjective perception of effort generated during a given activity. This instrument, proposed by Borg, consists of a 0 to 10-point scale (CR-10), where participants select the descriptor and number that best reflect their psychophysiological stress related to the exercise. Before the exercise, participants will receive instructions on how to accurately respond to the RPE scale. Participants will report their perceived effort while looking at the scale, where 0 indicates "no effort" and 10 indicates "maximal effort."

    Time frame: 9 weeks (at baseline, mid-intervention, and post-intervention, as well as before and immediately after training sessions)

  11. Myotonometry

    Muscle tone, stiffness, and elasticity of the quadriceps femoris will be assessed using the MyotonPRO® device (MyotonAS, Tallinn, Estonia). The device will be positioned at two-thirds of the distance between the anterior superior iliac spine (ASIS) and the superior pole of the patella, 4 cm above the base of the patella, 15 cm below the ASIS, at the midpoint between the patella and the anterior inferior iliac spine (AIIS), and 2 cm medially and 2 cm laterally from the midpoint. The device will be placed perpendicular to the assessed region, applying a light pre-load pressure, controlled at 0.18 N of initial compression of the subcutaneous tissue. Subsequently, an additional impulse of 0.40 N will be released for 15 ms, inducing tissue oscillation, which will then be dampened or attenuated.

    Time frame: 9 weeks (at baseline, mid-intervention, and post-intervention, as well as before and immediately after training sessions)

  12. Bioelectrical impedance analysis

    Bioimpedance will be measured using a tetrapolar device (BIA Analyzer, 50 kHz, 800 µA). Electrodes will be positioned on the quadriceps femoris muscles. Analyzed variables will include resistance (R), reactance (Xc), phase angle (PhA), and tolerance ellipse, via Bioscan software.

    Time frame: 9 weeks (at baseline, mid-intervention, and post-intervention, as well as before and immediately after training sessions)

  13. Functional mobility

    The Timed Up and Go (TUG) test is a simple and quick physical test used to assess and classify functional mobility and fall risk in older adults. A time of up to 10 seconds is considered normal for healthy and independent individuals; 11 to 20 seconds are considered partially independent, with impairment and/or low risk of falls; 21 to 29 seconds indicates a moderate risk of falls; and more than 30 seconds suggests impaired physical mobility and a high risk of falls.

    Time frame: 3 days (baseline, mid-intervention, and final assessment)

  14. Physical performance

    The Short Physical Performance Battery (SPPB) assesses physical performance and includes three domains: semi-static balance, lower limb strength, and gait speed. Each test has a maximum score of 4 points, and the total score is the sum of the three tests, with a maximum of 12 points. The final classification is as follows: 0-3 points - disability or poor performance; 4-6 points - low performance; 7-9 points - moderate performance; 10-12 points - good performance.

    Time frame: 3 days (baseline, mid-intervention, and final assessment)

  15. Agility and dynamic balance test

    The Agility and Dynamic Balance (AGIL) test is part of the AAHPERD test battery, in which tasks similar to daily functional fitness activities are performed. Reference values for older women: 10.3-19.5 seconds - very good; 19.6-21.4 seconds - good; 21.5-23.6 seconds - fair; 23.7-26.4 seconds - poor; 26.5-44.4 seconds - very poor.

    Time frame: 3 days (baseline, mid-intervention, and final assessment)

Other outcomes

  1. Occlusion pressures (AOP)

    To determine the AOP, the Doppler equipment transducer will be used, which will be positioned over the posterior tibial artery to capture the auscultatory pulse. A blood pressure cuff will be fixed to the participant's thigh close to the region of the inguinal fold of the dominant limb, and then with the inflatable region of the cuff on the medial portion of the thigh covering the femoral artery, it will be progressively inflated, waiting 15 seconds every 30 mmHg until the point at which the auscultatory pulse of the tibial artery is interrupted.

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

Of 65 non-industry interventional studies with no phase under Hypertrophy, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 22. This study's planned 15 months is close to that.

Counting every sponsor, half of 78 studies reached it within 13 months; a quarter within 6 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Sep 4, 2025
StartActual
Aug 11, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Aug 1, 2027
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07155967
Lead sponsor
Paulista University
Responsible party
Franciele Marques Vanderle (Principal Investigator, Paulista University) — Principal investigator
First posted
Sep 4, 2025
Start date
Aug 11, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Sep 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion